Alterity Therapeutics

Alterity Therapeutics Ltd ADR is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders. The company’s current research centers on diseases such as Parkinson’s disease and multiple system atrophy, with a pipeline built around small-molecule drug candidates designed to address underlying disease mechanisms. Its lead programs are aimed at reducing pathological protein aggregation, modulating excess labile iron, and supporting neuronal function in the brain. Alterity Therapeutics also develops biomarker and clinical-stage assets to better understand progression in neurodegenerative conditions. Headquartered in Melbourne, Australia, the company operates in the global pharmaceutical and biotechnology market, where it contributes to ongoing efforts in targeted treatments for complex brain disorders. As an ADR, Alterity Therapeutics Ltd provides U.S. investors access to the company’s ordinary shares through a listed depositary receipt structure.